R&D News | pharmaphorum

News

Merck's challenge to Pfizer's Prevnar grows

Pfizer's longstanding dominance of the pneumococcal vaccines category could be threatened by Merck & Co, which has just reported new data on its V116 shot in older adu

News

AZ builds in genomic medicine with $1bn Pfizer deal

AstraZeneca's rare diseases unit Alexion has agreed to pay $1 billion to acquire Pfizer's early-stage gene therapy pipeline and enabling technologies - the company's first

News

Enhertu shows survival boost in HER2+ solid tumours

AstraZeneca and Daiichi Sankyo's chances of getting approval for Enhertu as a therapy for all HER2-positive tumours – regardless of their location in the body – have just

News

Roche removes tenecteplase from phase 3 for stroke

Roche said it has removed its thrombolytic drug tenecteplase from phase 3 for for acute ischaemic stroke, along with several earlier-stage projects.

News

Medicxi co-founder and partner Francesco De Rubertis

Medicxi primes its latest $400m biotech fund

Anglo-Swiss life sciences investment company Medicxi has raised $400 million for its fourth fund, which will focus on supporting 'asset-centric' companies at all stages of

News

MSD, Moderna start phase 3 trial of mRNA cancer jab

MSD & Co and Moderna have advanced a combination of an mRNA-based cancer vaccine and checkpoint inhibitor Keytruda into a phase 3 trial in skin cancer melanoma, althou

Merck's challenge to Pfizer's Prevnar grows

AZ builds in genomic medicine with $1bn Pfizer deal

Enhertu shows survival boost in HER2+ solid tumours

Roche removes tenecteplase from phase 3 for stroke

Medicxi primes its latest $400m biotech fund

MSD, Moderna start phase 3 trial of mRNA cancer jab

Merck partners Remepy in PDURS-focused alliance

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks